Navigation Links
Quantason Names Dr. Ellen B. Mendelson, Medical Director
Date:2/26/2013

LOS ANGELES, Feb. 26, 2013 /PRNewswire/ -- Quantason, the innovator in screening technologies for the early detection of high-risk breast lesions, has named Dr. Mendelson, as Medical Director.

(Logo: http://photos.prnewswire.com/prnh/20121022/LA97501LOGO)

Dr. Mendelson is Lee F. Rogers Professor of Radiology and Medical Education at the Feinberg School of Medicine, Northwestern University, Section Chief and Fellowship Program Director in Breast and Women's Imaging at Northwestern Memorial Hospital in Chicago.  She is an expert in mammography, breast ultrasound and MRI with current interest in automated volumetric ultrasound scanners.  Dr. Mendelson is active in the American College of Radiology (ACR), a member of the Breast Commission where she chairs the Economics Committee and the committee that prepared the first edition of BI-RADS® (Breast Imaging Reporting and Data System) for Ultrasound.  She and her committee are currently readying the 2nd edition for publication.

"There is a lot in common between Quantason's quest to develop a dual-mode active ultrasound technology for the detection and location of high-risk lesions and Dr. Mendelson's interests in breast diagnosis, image-guided interventional procedures, and adjunctive screening with ultrasound," said Dr. Edmond Rambod, President and CEO of Quantason and added, "Ellen's unique expertise as the co-investigator in the multicenter ACRIN 6666 study comparing ultrasound with mammography in high risk women with dense breast tissue and in the comparative lesion detection study performed by handheld transducers versus automated scanners, is invaluable as we share the same views and goals of proactively screening for the early detection of high-risk markers by IDUS™".

"Ellen is widely published and an invited speaker on all aspects of breast imaging.  She has co-authored the textbook, The Practice of Breast Ultrasound, is a co-organizer of the annual, The Chicago International Breast Course, and serves as the faculty of the International Breast Ultrasound School", said Dr. Rambod and summarized, "Ellen brings outstanding medical, scientific and practical experience along with a passion for the earliest, safest and least costly detection of breast high-risk lesions and cancer".  Dr. Mendelson said, "I am pleased and proud to be associated with Quantason in developing a reliable, radiation-free, low-risk, low-cost and accessible automated system to early detect microcalcifications associated with high-risk and carcinoma in situ breast lesions".  She concluded that, "in this era of great controversies in breast cancer detection, we are working to enhance our knowledge and experience by adopting new technologies such as IDUSTM which both utilizes the traditional ultrasound systems and significantly improves their performance in providing a robust method for imaging, diagnosis and screening for early detection and follow-up monitoring".

About Quantason
Quantason has developed IDUS™, a revolutionary, next-generation bi-modal platform which fundamentally changes the utilization of conventional ultrasound as a modality for diagnostic imaging and active screening.  Quantason's patented and patent-pending technology expands the capabilities of conventional ultrasound systems by combining anatomical 2D imaging with proprietary, real-time stimulation sequences to detect, 3D locate, and classify micron-size target(s) - previously conceived outside of ultrasound capabilities - based on their response signature(s).  For more information, visit www.quantason.com.


'/>"/>
SOURCE Quantason
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Nano Mask Names Dr. Hassan Bennani to Board of Directors
2. SPIE Names 69 New Fellows of the Society in 2013
3. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
4. AtheroNova Names New Director
5. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
6. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
7. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
8. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
9. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
10. Lloyd Library and Museum Names ABCs Blumenthal to New Honorary Advisory Board
11. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Wellcentive today announced it has ... Oregon -based community care organization (CCO) with ... analytics, quality reporting and care management solutions and ... team of quality managers, analysts and care managers ... groups serving FamilyCare members. ...
(Date:2/11/2016)... , February 11, 2016 ... Corporation ("PositiveID" or "Company") (OTCQB: PSID), a life ... today that its Thermomedics subsidiary, which markets the ... its growth plan in January 2016, including entering ... increasing sequential monthly sales growth, and establishing several ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome ... Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, ...
(Date:2/10/2016)... Early-career researchers from Indonesia ... Uganda and Yemen ... Indonesia , Nepal , ... Yemen are being honored for their accomplishments in nutrition, psychiatry, ... mentoring young women scientists who are pursuing careers in agriculture, biology and ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):